about
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicityDifferential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancerExtra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis.Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis.Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant SettingSubpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer.MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives.Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'?Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting.Tubulin inhibitors in non-small cell lung cancer: looking back and forward.Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art.Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors.Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification.Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.Tracking MET de-addiction in lung cancer: A road towards the oncogenic target.The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors.Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy.Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over?Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with tImpact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials.Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancerHER2/neu gene determination in women screened for breast carcinoma: how screening programs reduce the skyrocketing cost of targeted therapyA multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer StudyT-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancerThe obesity paradox in cancer: clinical insights and perspectivesPrognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing PerspectivesPalbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experienceRevising PTEN in the Era of Immunotherapy: New Perspectives for an Old StoryAvoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world settingPD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis
P50
Q26769744-18D0FBC2-84EA-4BCD-96B1-CDF46EF1E2F8Q27853176-C8FF12A3-DD42-45DE-8B30-2660241786FDQ28072004-F0E46979-04C8-4C7D-9E13-04823FEC6698Q30251731-4674B4D2-F72A-43C2-8951-E92DBA892314Q31157714-4CE1387E-1131-4B78-B893-B4675697AE16Q36472959-BE867C46-22E0-401D-9B5C-16464960E6BAQ36670779-FB3C8BDF-70C9-4B45-8A30-548FD6E16561Q36673469-6E25FB90-A8A4-4DF8-AB6E-49D1A3F41BEBQ36715181-A8DD9FF3-3BC8-4977-BCDF-12AF8A859464Q37597858-7D47DEA4-3B11-4F3B-B4BB-06FFD45CA0D1Q38261389-D58F3BB6-7365-4269-B2F7-AA2A63B1488EQ38266331-5BB92C0F-F8F0-4BC4-9C79-34FFD7161B09Q38356255-D0BDAB5F-41CE-4DD5-A61B-B3BAD8D85005Q38525073-D83FBD62-CBF0-40DA-880F-7C361B660C03Q38550459-BB688F9A-53AD-4A23-8EDF-8D161C18A905Q38677841-A4F5221D-E3D7-4DC7-B3D0-F37143571D4BQ38742506-004F0F88-6566-42C5-ACF9-575F7D037D32Q39452421-0CAA9FE9-3586-4E94-9723-C3E969FF432EQ40709010-9F9E4EBC-5E4A-4C3E-9667-52CAD93D3480Q41821797-F3443E9F-DB0A-4B17-8FDF-735A952727DBQ42362796-3E43F22B-310F-4EF0-BC2E-C9615814A57CQ45066071-9E16230A-6C8E-4145-8DE8-3146D2B3EB3BQ46984294-5DBBB00D-34CE-4B03-ABC4-E49098445CFDQ50070316-2C565CD5-2F01-4652-9017-9CD9ADF1522BQ51133187-5AE2B99C-E3BE-4E0C-AD52-0ECCCEDF38E4Q52629448-EC0325E0-3636-4666-8D9B-F44A9D447C0AQ53127741-4B27CA68-43A4-4946-9040-06DB694C183EQ54337320-7164BBB3-F487-4362-99A5-50DD6511CDD5Q54348933-34536D61-D694-4CCC-BBAD-9E9B11C15F13Q57106750-7BDAB519-CEA1-4F6A-BD44-2F9B8546BD58Q57424074-810A6FA1-7178-49EB-8B8D-790D2E08471FQ58593563-BC812607-D832-45B9-9C63-E1A7CA6E9163Q62661825-B57F688D-00A6-4DA0-8EBC-6521187C8623Q87917233-B80F4364-7AC1-48A3-8BC7-8C4472616291Q90226704-DB7AAD61-482A-46E3-921A-53FFB24BBC62Q90400192-D05B5D8C-E33C-42A2-A325-24B993F42FE1Q90972622-ABABBC90-5560-4ADB-9447-A85FE2DA74A3Q91822500-744A8995-C724-4C45-9AE7-24670605DFBCQ92076196-BF88CC27-0020-4654-8B06-0D963FDE7C3CQ92475653-1C273CD6-FC78-469D-96F1-2C7A50A6B5EF
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Luisa Carbognin
@ast
Luisa Carbognin
@en
Luisa Carbognin
@es
Luisa Carbognin
@nl
Luisa Carbognin
@sl
type
label
Luisa Carbognin
@ast
Luisa Carbognin
@en
Luisa Carbognin
@es
Luisa Carbognin
@nl
Luisa Carbognin
@sl
prefLabel
Luisa Carbognin
@ast
Luisa Carbognin
@en
Luisa Carbognin
@es
Luisa Carbognin
@nl
Luisa Carbognin
@sl
P1053
J-8171-2016
P106
P21
P31
P3829
P496
0000-0003-3532-0963